412 related articles for article (PubMed ID: 15148558)
1. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
[TBL] [Abstract][Full Text] [Related]
2. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
3. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
Mossetti G; Rendina D; De Filippo G; Viceconti R; Di Domenico G; Cioffi M; Postiglione L; Nunziata V
Bone; 2005 Mar; 36(3):549-54. PubMed ID: 15777635
[TBL] [Abstract][Full Text] [Related]
8. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
Siris ES; Lyles KW; Singer FR; Meunier PJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
Arboleya L; Sánchez J; Iglesias G; Arranz JL
Rev Clin Esp; 1993 Dec; 193(9):467-71. PubMed ID: 8108576
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate resistance in Paget's disease of bone.
Joshua F; Epstein M; Major G
Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
[TBL] [Abstract][Full Text] [Related]
11. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
12. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
13. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
[TBL] [Abstract][Full Text] [Related]
14. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
15. Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Zwinderman AH; Vermeij P; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1993 Feb; 8(2):175-82. PubMed ID: 8442435
[TBL] [Abstract][Full Text] [Related]
16. Short courses of intravenous clodronate in the treatment of Paget's disease of bone: a long-term follow-up trial.
Broggini M; Baratelli E; Cappelli A; Marconi A; Ghiringhelli D; Salzillo A
Int J Clin Pharmacol Res; 1993; 13(6):301-4. PubMed ID: 8088930
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
[TBL] [Abstract][Full Text] [Related]
18. Determinants of remission of Paget's disease of bone.
Patel S; Stone MD; Coupland C; Hosking DJ
J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
[TBL] [Abstract][Full Text] [Related]
19. [Paget's disease and its therapeutic management].
Orcel P; Rousière M
Presse Med; 2005 Apr; 34(8):612-6. PubMed ID: 15962504
[TBL] [Abstract][Full Text] [Related]
20. Pamidronate infusions for the treatment of Paget's disease of bone.
Mazieres B; Ahmed I; Moulinier L; Bon E; Cantagrel A; Laroche M
Rev Rhum Engl Ed; 1996 Jan; 63(1):36-43. PubMed ID: 9064108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
